

11-29-01

11054 U.S. PTO

Please type a plus sign (+) inside this box → ☐

Approved for use through 10/31/2002. OMB 0651-003
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No. CN01365K
First Inventor Palani et al.
Title MCH ANTAGONISTS AND THEIR USE IN THE TREATMENT OF OBESITY
Express Mail Label No. EJ393737142US

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

1. ☒ Fee Transmittal Form (e.g., PTO/SB/17)
(Submit an original and a duplicate for fee processing)
2. ☐ Applicant claims small entity status.
See 37 CFR 1.27.
3. ☒ Specification [Total Pages 104]
(preferred arrangement set forth below)
 - Descriptive title of the invention
 - Cross Reference to Related Applications
 - Statement Regarding Fed sponsored R & D
 - Reference to sequence listing, a table, or a computer program listing appendix
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Description of the Drawings (if filed)
 - Detailed Description
 - Claim(s)
 - Abstract of the Disclosure
4. ☐ Drawing(s) (35 U.S.C. 113) [Total Sheets]
5. Oath or Declaration [Total Pages 4]
 - a. ☒ Newly executed (original or copy)
Copy from a prior application (37 CFR 1.63 (d))
 - b. ☐ (for continuation/divisional with Box 18 completed)
 - i. ☐ **DELETION OF INVENTOR(S)**
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).
6. ☐ Application Data Sheet. See 37 CFR 1.76

ADDRESS TO: Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231

7. ☐ CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)
8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)
 - a. ☐ Computer Readable Form (CRF)
 - b. Specification Sequence Listing on:
 - i. ☐ CD-ROM or CD-R (2 copies); or
 - ii. ☐ paper
 - c. ☐ Statements verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

9. ☐ Assignment Papers (cover sheet & document(s))
10. ☐ 37 CFR 3.73(b) Statement of Attorney (when there is an assignee) ☐ Power of Attorney
11. ☐ English Translation Document (if applicable)
12. ☐ Information Disclosure Statement (IDS)/PTO-1449 ☐ Copies of IDS Citations
13. ☐ Preliminary Amendment
14. ☒ Return Receipt Postcard (MPEP 503) (Should be specifically itemized)
15. ☐ Certified Copy of Priority Document(s) (if foreign priority is claimed)
16. ☐ Nonpublication Request under 35 U.S.C. 122 (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent.
17. ☒ Other: Cover Sheet (T pg.)

18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.: _____
Prior application information: Examiner _____ Group Art Unit: _____

For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

19. CORRESPONDENCE ADDRESS

☒ Customer Number or Bar Code Label 24265 or ☐ Correspondence address below

Name Elliott Korsen, (Reg. No. 32,705)
Address
City State Zip Code
Country Telephone 908-298-5684 Fax 908-298-5388

Name (Print/Type) Elliott Korsen Registration No. (Attorney/Agent) 32,705
Signature Date November 28, 2001

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

Express Mail Label No.: EJ393737142US

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Approved for use through 10/31/2002. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

PTO/SB/17 (10-01)

**FEE TRANSMITTAL
for FY 2002**

Patent fees are subject to annual revision.

TOTAL AMOUNT OF PAYMENT

(\$ 812.00)

Complete if Known

Application Number

Filing Date

November 28, 2001

First Named Inventor

Palani et al.

Examiner Name

Group Art Unit

Attorney Docket No.

CN01365K

METHOD OF PAYMENT

- 1.
- ☒
- The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to:

Deposit
Account
Number

19-0365

Deposit
Account
Name

Schering-Plough Corporation

- ☒
- Charge Any Additional Fee Required
-
- Under 37 CFR 1.16 and 1.17

- ☐
- Applicant claims small entity status.
-
- See 37 CFR 1.27

- 2.
- ☐
- Payment Enclosed:

☐ Check☐ Credit card☐ Money
Order☐ Other**FEE CALCULATION****1. BASIC FILING FEE**

Large Entity Small Entity

Fee Fee Fee Fee Fee Description

Code (\$) Code (\$) Code (\$)

101 740 201 370 Utility filing fee

106 330 206 165 Design filing fee

107 510 207 255 Plant filing fee

108 740 208 370 Reissue filing fee

114 160 214 80 Provisional filing fee

Fee Paid

740.00

SUBTOTAL (1) (\$ 740.00)

2. EXTRA CLAIM FEES

Extra Claims

Fee from
below

Fee Paid

Total Claims

24

-20** =

4

x

18

=

72

Independent
Claims

1

-3** =

0

x

0

=

0

Multiple Dependent

Large Entity Small Entity

Fee Fee Fee Fee Fee Description

Code (\$) Code (\$) Code (\$)

103 18 203 9 Claims in excess of 20

102 84 202 42 Independent claims in excess of 3

104 280 204 140 Multiple dependent claim, if not paid

109 84 209 42 ** Reissue independent claims
over original patent110 18 210 9 ** Reissue claims in excess of 20
and over original patent

SUBTOTAL (2)

(\$ 72.00)

**or number previously paid, if greater; For Reissues, see above

FEE CALCULATION (continued)**3. ADDITIONAL FEES**Large
EntitySmall
Entity

Fee Fee Fee Fee

Code (\$) Code (\$)

Fee Description

Fee Paid

105 130 205 65

Surcharge - late filing fee or oath

127 50 227 25

Surcharge - late provisional filing fee or
cover sheet

139 130 139 130

Non-English specification

147 2,520 147 2,520

For filing a request for *ex parte* reexamination

112 920* 112 920*

Requesting publication of SIR prior to
Examiner action

113 1,840* 113 1,840*

Requesting publication of SIR after
Examiner action

115 110 215 55

Extension for reply within first month

116 400 216 200

Extension for reply within second month

117 920 217 460

Extension for reply within third month

118 1,440 218 720

Extension for reply within fourth month

128 1,960 228 980

Extension for reply within fifth month

119 320 219 160

Notice of Appeal

120 320 220 160

Filing a brief in support of an appeal

121 280 221 140

Request for oral hearing

138 1,510 138 1,510

Petition to institute a public use proceeding

140 110 240 55

Petition to revive - unavoidable

141 1,280 241 640

Petition to revive - unintentional

142 1,280 242 640

Utility issue fee (or reissue)

143 460 243 230

Design issue fee

144 620 244 310

Plant issue fee

122 130 122 130

Petitions to the Commissioner

123 50 123 50

Processing fee under 37 CFR 1.17(q)

126 180 126 180

Submission of Information Disclosure Stmt

581 40 581 40

Recording each patent assignment per
property (times number of properties)

146 740 246 370

Filing a submission after final rejection
(37 CFR § 1.129(a))

149 740 249 370

For each additional invention to be
examined (37 CFR § 1.129(b))

179 740 279 370

Request for Continued Examination (RCE)

169 900 169 900

Request for expedited examination
of a design application

Other fee (specify)

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$ 0.00)

SUBMITTED BY

Name (Print/Type)

Elliott Korsen

Registration No.
(Attorney/Agent)

32,705

Complete (if applicable)

Telephone

(908) 298-5684

Signature



Date

November 28, 2001

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



U.S. APPLICATION DATA SHE

Case No. CN01365K

Attorney EK:sa

New Original Application:

Originating Disclosure No. _____ Regular and Provisional filed together ☐

Regular application filed only ☐

Provisional application filed only ☐

Continuing Application:

Continuation-in-Part ☐ Continuation ☐ CPA ☐ Divisional ☐

Check box if this is a refiled provisional application ☒

Priority: This application claims priority from Serial No. 60/250502 filed 12/01/00

Important: If this is a CIP application filed more than 1 year from the above priority date and it should be considered for foreign filing, place an X in box ☐

Date of filing _____ Express Mail ☒ Hand filing ☐

Title MCH ANTAGONISTS AND THEIR USE IN THE TREATMENT OF OBESITY

(give complete title)

Inventors (list as they appear on Declaration and give full name including middle initial)

(1) Anandan Palani (5) John Clader

(2) Mark D. McBriar (6) _____

(3) Sherry A. Shapiro (7) _____

(4) Ruo Xu (8) _____

Additional inventors listed on separate sheet ☐

Deposit Account:

Application Filing Fee \$ 740.00 8/2/00 **EK**

Provisional Application Fee \$ _____

Other Fee(s) \$ _____

\$ _____

TOTAL FEES CHARGED TO

DEPOSIT ACCOUNT 19-0365 \$ 740.00 8/2/00 **EK**

DESCRIPTION: (The following description will appear on PCM Agenda)

This application covers This invention relates to antagonists of melanin-concentrating hormone (MCH) and their use in the treatment of eating disorders, metabolic disorders and diabetes.

Attorney Initials EK

Date: November 28, 2001

Entered _____